ArticleDiscover oncology2026
The value of immunogenic cell death-related gene model in the prognosis of gastric cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Immunogenic cell death (ICD) is a form of regulatory cell death that has been obtained growing attention for its role in the treatment and prognosis of tumors. This study aims to further investigate the value of immunogenic cell death-related genes (ICDRGs) in prognostic of GC. We obtained the stomach adenocarcinoma (STAD) dataset from the Gene Expression Omnibus (GEO) database and the Cancer Genome Atlas (TCGA) database, got ICDRGs from the GeneCards database, and utilized LASSO regression to construct a prognostic model. Based on the median risk score, patients were separated into high-risk and low-risk groups and differential gene expression analysis related to prognosis was obtained. We further studied the possible mechanisms, biological characteristics, and pathways of genes in different risk groups. Prognostic analysis, chromosomal localization, and ROC curve plotting were performed. Immunohistochemical analysis was conducted using the Human Protein Atlas (HPA) database. We constructed a prognostic model based on 22 ICDRGs and conducted enrichment analysis to obtain relevant biological characteristics and pathways. An 8-hub gene PPI network model was obtained. ROC curves showed that the occurrence of STAD is associated with the expression of 8 hub genes. Immunohistochemical analysis revealed higher expression levels of genes HSP90AA1, HMGB1, IFNGR1, PDIA3 in STAD tumor tissues compared to normal tissues. This research developed a prognostic model for STAD using ICDRGs and investigated the potential influence of these genes in patients with GC, providing a new direction for evaluating GC prognosis and guiding individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.